Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients

Saturday, May 15, 2010 Research News
Email Print This Page Comment
Font : A-A+

Submission Includes Data from Three Pivotal Phase 3 Trials

CONTACT: Amgen, Thousand Oaks

Christine Regan: +1 (805) 447-5476 (media)

Arvind Sood: +1 (805) 447-1060 (investors)



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook